With India taking decisive steps in lieu with the guidelines from the World Health Organisation to tackle the spread of the pandemic COVID-19, it is expected that it will be able to significantly control the aggressive spread of the disease. The Modi-led central government has ordered a complete lockdown of the entire country for 21 days starting March 25, 2020 till April 14, 2020.
Apart from it, the Indian government has banned the export of hydroxychloroquine and formulations made from the medication, as experts test the efficacy of the drug in helping treat patients infected with COVID-19. Research regarding the cure is being conducted and researchers have been working on existing treatments as well as experimental ones. Of the existing treatments, Hydroxychloroquine, a malaria drug, is one among others thus resulting in the bar of its export.
The novel coronavirus can cause deadly respiratory illness and is highly contagious, and the most difficult part about it is that there are currently no approved treatments, or preventive vaccines for COVID-19. The patients of COVID-19 in India by far are getting only supportive care such as breathing assistance.
Per the data provided by the American Society of Health-System Pharmacists (ASHP) earlier this week, it is indicated that hydroxychloroquine was in shortage. The American Society of Health-System Pharmacists (ASHP) maintains a list of shortages of drugs.